Latest Breaking News On - Research data preclinical programs - Page 1 : comparemela.com

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology 65th Annual Meeting • Execution of strategic.

New yorkUnited statesFrance generalNorth carolinaBingc wangPascalyne wilsonArthur strilAllogene alloAnnick schwebigAshleyr robinsonMarc dunoyerPatricia sosa navarroAmerican society of geneTaz holdingsEuropean hematology associationCalyxt inc

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

• Strategic Collaboration and Investment Agreements signed with AstraZenecaUpdated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/.

United statesNew yorkFrance generalNorth carolinaArthur strilLes laboratoires servierPatricia sosa navarroAshleyr robinsonAllogeneic car development programsMd anderson cancer centerInternational financial reporting standardsAllogene therapeutics incCellectis the company euronext growthCibus globalGroup shareEuropean society

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

France generalNew yorkUnited statesNorth carolinaAshleyr robinsonPascalyne wilsonAnnick schwebigArthur strilResearch at iovance biotherapeutics incInternational financial reporting standardsInternational society for cellClinical development programsNextvivo incAmerican society of clinical oncologyGroup shareCancer immunology research

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

North carolinaUnited statesNew yorkFrance generalAshleyr robinsonPascalyne wilsonAnnick schwebigArthur strilEuropean medicines agencyInternational conference on malignant lymphomaInternational society for cell gene therapyAmerican society of geneAllogeneic car development programsCibus globalEuropean hematology associationEuropean hematology association congress

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s. | May 4, 2023

United statesNorth carolinaFrance generalNew yorkAshleyr robinsonPascalyne wilsonArthur strilInternational accounting standards boardBarclays capital incResearch data preclinical programsAmerican society of hematologyAmerican society of clinical oncologyCibus globalAmerican society of geneEuropean investment bankExchange commission